No neurodevelopmental benefit of cerebral oximetry in the first randomised trial (SafeBoosC <scp>II</scp>) in preterm infants during the first days of life

Abstract

Cerebral NIRS monitoring was not associated with long-term benefits or harm with regard to neurodevelopmental outcome at two years of corrected age.